Comparison of Normal Versus Imiquimod-induced Psoriatic Skin in Mice for Penetration of Drugs and Nanoparticles

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2018 Oct 2

PMID 30271151

Citations 14

Authors

Lin Sun

Zeyu Liu

Zibei Lin

Dongmei Cun

Henry Hy Tong

Ru Yan

Ruibing Wang

Ying Zheng

Affiliations

Soon will be listed here.

Abstract

Background: As an immune-mediated skin disease, psoriasis encounters therapeutic challenges on topical drug development due to the unclear mechanism, and complicated morphological and physiological changes in the skin.

Methods: In this study, imiquimod-induced psoriatic mouse skin (IMQ-psoriatic skin) was chosen as the in vitro pathological model to explore the penetration behaviors of drugs and nanoparticles (NPs).

Results: Compared with normal skin, significantly higher penetration and skin accumulation were observed in IMQ-psoriatic skin for all the three model drugs. When poorly water-soluble curcumin was formulated as NPs that were subsequently loaded in gel, the drug's penetration and accumulation in both normal and IMQ-psoriatic skins were significantly improved, in comparison with that of the curcumin suspension. Interestingly, the NPs' size effect, in terms of their penetration and accumulation behaviors, was more pronounced for IMQ-psoriatic skin. Furthermore, by taking three sized FluoSpheres as model NPs, confocal laser scanning microscopy demonstrated that the penetration pathways of NPs no longer followed the hair follicles channels, instead they were more widely distributed in the IMQ-psoriatic skin.

Conclusion: In conclusion, the alternation of the IMQ-psoriatic skin structure will lead to the enhanced penetration of drug and NPs, and should be considered in topical drug formulation and further clinical practice for psoriasis therapy.

Citing Articles

Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.

Pacheco-Garcia U, Varela-Lopez E, Serafin-Lopez J Int J Mol Sci. 2024; 25(14).

PMID: 39062904 PMC: 11277483. DOI: 10.3390/ijms25147661.

Oil-loaded Ethanolic Vesicular Gel for Imiquimod-induced Plaque Psoriasis: Physicochemical Characterization, Rheological Studies, and Efficacy.

Vihal S, Pundir S, Rathore C, Lal U, Gupta G, Singh S Curr Drug Deliv. 2024; 22(1):80-91.

PMID: 38956909 DOI: 10.2174/0115672018246645231019131748.

Development of Betulin-Loaded Nanostructured Lipid Carriers for the Management of Imiquimod-Induced Psoriasis.

Biswasroy P, Pradhan D, Pradhan D, Ghosh G, Rath G AAPS PharmSciTech. 2024; 25(3):57.

PMID: 38472545 DOI: 10.1208/s12249-024-02774-1.

Implications of interleukin-17 in psoriatic lesions as Koebner phenomenon caused by recurrent occupational burns.

Sato A, Fukumoto T, Yoshioka A, Nishigori C Dermatol Reports. 2023; 15(2):9567.

PMID: 37397401 PMC: 10312102. DOI: 10.4081/dr.2022.9567.

Topical Diacerein Decreases Skin and Splenic CD11c Dendritic Cells in Psoriasis.

Brunner S, Ramspacher A, Rieser C, Leitner J, Heil H, Ablinger M Int J Mol Sci. 2023; 24(5).

PMID: 36901755 PMC: 10001455. DOI: 10.3390/ijms24054324.

References

Lin Y, Yang S, Chen C, Kao H, Fang J . Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs. PLoS One. 2015; 10(9):e0137890. PMC: 4565663. DOI: 10.1371/journal.pone.0137890. View

Prow T, Grice J, Lin L, Faye R, Butler M, Becker W . Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011; 63(6):470-91. DOI: 10.1016/j.addr.2011.01.012. View

Brodin A, Wadsten T, Forslund B, Broberg F . Phase diagram and aqueous solubility of the lidocaine-prilocaine binary system. J Pharm Sci. 1984; 73(4):481-4. DOI: 10.1002/jps.2600730413. View

Meng F, Trivino A, Prasad D, Chauhan H . Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. Eur J Pharm Sci. 2015; 71:12-24. DOI: 10.1016/j.ejps.2015.02.003. View

Wu J, Siller G, Strutton G . Psoriasis induced by topical imiquimod. Australas J Dermatol. 2004; 45(1):47-50. DOI: 10.1111/j.1440-0960.2004.00030.x. View

Garidel P, Folting B, Schaller I, Kerth A . The microstructure of the stratum corneum lipid barrier: mid-infrared spectroscopic studies of hydrated ceramide:palmitic acid:cholesterol model systems. Biophys Chem. 2010; 150(1-3):144-56. DOI: 10.1016/j.bpc.2010.03.008. View

Lowes M, Suarez-Farinas M, Krueger J . Immunology of psoriasis. Annu Rev Immunol. 2014; 32:227-55. PMC: 4229247. DOI: 10.1146/annurev-immunol-032713-120225. View

Slominski A, Zmijewski M, Zbytek B, Tobin D, Theoharides T, Rivier J . Key role of CRF in the skin stress response system. Endocr Rev. 2013; 34(6):827-84. PMC: 3857130. DOI: 10.1210/er.2012-1092. View

Lowes M, Bowcock A, Krueger J . Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130):866-73. DOI: 10.1038/nature05663. View

10.

Sun L, Cun D, Yuan B, Cui H, Xi H, Mu L . Formulation and in vitro/in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron. J Pharm Sci. 2012; 101(12):4540-8. DOI: 10.1002/jps.23317. View

11.

Mason A, Mason J, Cork M, Dooley G, Hancock H . Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013; (3):CD005028. PMC: 11227123. DOI: 10.1002/14651858.CD005028.pub3. View

12.

Hartwig T, Pantelyushin S, Croxford A, Kulig P, Becher B . Dermal IL-17-producing γδ T cells establish long-lived memory in the skin. Eur J Immunol. 2015; 45(11):3022-33. DOI: 10.1002/eji.201545883. View

13.

Mahler G, Esch M, Tako E, Southard T, Archer S, Glahn R . Oral exposure to polystyrene nanoparticles affects iron absorption. Nat Nanotechnol. 2012; 7(4):264-71. DOI: 10.1038/nnano.2012.3. View

14.

Dias M, Hadgraft J, Lane M . Influence of membrane-solvent-solute interactions on solute permeation in skin. Int J Pharm. 2007; 340(1-2):65-70. DOI: 10.1016/j.ijpharm.2007.03.030. View

15.

Ho H, Chen L, Lin H, Sheu M . Penetration enhancement by menthol combined with a solubilization effect in a mixed solvent system. J Control Release. 1998; 51(2-3):301-11. DOI: 10.1016/s0168-3659(97)00184-3. View

16.

Sun J, Zhao Y, Hu J . Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One. 2013; 8(6):e67078. PMC: 3692410. DOI: 10.1371/journal.pone.0067078. View

17.

Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y . PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem. 2011; 59(17):9280-9. DOI: 10.1021/jf202135j. View

18.

Zhai Y, Zhai G . Advances in lipid-based colloid systems as drug carrier for topic delivery. J Control Release. 2014; 193:90-9. DOI: 10.1016/j.jconrel.2014.05.054. View

19.

Vogt A, Combadiere B, Hadam S, Stieler K, Lademann J, Schaefer H . 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol. 2006; 126(6):1316-22. DOI: 10.1038/sj.jid.5700226. View

20.

Yoshiki R, Kabashima K, Honda T, Nakamizo S, Sawada Y, Sugita K . IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells. J Invest Dermatol. 2014; 134(7):1912-1921. DOI: 10.1038/jid.2014.98. View